Laboratory Corp. of America (LH) Earns Buy Rating from Analysts at Goldman Sachs Group

Investment analysts at Goldman Sachs Group began coverage on shares of Laboratory Corp. of America (NYSE:LH) in a research note issued on Monday, January 29th, Marketbeat Ratings reports. The firm set a “buy” rating and a $205.00 price target on the medical research company’s stock. Goldman Sachs Group’s target price points to a potential upside of 22.53% from the stock’s current price.

Several other equities research analysts have also weighed in on the company. Mizuho set a $178.00 price objective on Laboratory Corp. of America and gave the company a “hold” rating in a research note on Wednesday, January 24th. ValuEngine lowered Laboratory Corp. of America from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Zacks Investment Research upgraded Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. Evercore ISI began coverage on Laboratory Corp. of America in a research note on Thursday, January 4th. They issued an “outperform” rating and a $176.00 price objective on the stock. Finally, Barclays reiterated a “buy” rating and issued a $195.00 price objective on shares of Laboratory Corp. of America in a research note on Wednesday, December 13th. Six investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $175.00.

Shares of Laboratory Corp. of America (LH) traded down $2.35 on Monday, reaching $167.31. The company had a trading volume of 341,858 shares, compared to its average volume of 564,177. Laboratory Corp. of America has a 1 year low of $128.00 and a 1 year high of $181.71. The company has a quick ratio of 1.75, a current ratio of 1.89 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $17,271.39, a price-to-earnings ratio of 23.40, a price-to-earnings-growth ratio of 1.61 and a beta of 0.93.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LH. Thrivent Financial For Lutherans grew its position in Laboratory Corp. of America by 11.7% during the 2nd quarter. Thrivent Financial For Lutherans now owns 4,200 shares of the medical research company’s stock worth $647,000 after acquiring an additional 440 shares during the last quarter. Mutual of America Capital Management LLC grew its position in Laboratory Corp. of America by 3.7% during the 2nd quarter. Mutual of America Capital Management LLC now owns 12,447 shares of the medical research company’s stock worth $1,919,000 after acquiring an additional 441 shares during the last quarter. Advisor Group Inc. grew its position in Laboratory Corp. of America by 20.9% during the 2nd quarter. Advisor Group Inc. now owns 3,950 shares of the medical research company’s stock worth $609,000 after acquiring an additional 684 shares during the last quarter. Stifel Financial Corp grew its position in Laboratory Corp. of America by 3.8% during the 2nd quarter. Stifel Financial Corp now owns 50,168 shares of the medical research company’s stock worth $7,729,000 after acquiring an additional 1,837 shares during the last quarter. Finally, Balyasny Asset Management LLC lifted its holdings in Laboratory Corp. of America by 86.4% during the 2nd quarter. Balyasny Asset Management LLC now owns 83,068 shares of the medical research company’s stock worth $12,804,000 after buying an additional 38,492 shares in the last quarter. Institutional investors and hedge funds own 90.87% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Laboratory Corp. of America (LH) Earns Buy Rating from Analysts at Goldman Sachs Group” was posted by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.thestockobserver.com/2018/02/02/laboratory-corp-of-america-lh-now-covered-by-analysts-at-goldman-sachs-group.html.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Analyst Recommendations for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply